Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Discontinued
Reference number: GID-TA10933
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in mid-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2024.